Kukje Pharma Co., Ltd. (002720) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kukje Pharma Co., Ltd. (002720:KRX), powered by AI.

Current Price
₩3,630
P/E Ratio
13.5
Market Cap
76.8B
Sector
Healthcare
What is the Kukje Pharma Co., Ltd. stock price forecast?

Kukje Pharma Co., Ltd. is currently trading at ₩3,630. View real-time AI analysis on Alpha Lenz.

What is Kukje Pharma Co., Ltd. insider trading activity?

View the latest insider trading data for Kukje Pharma Co., Ltd. on Alpha Lenz.

What is Kukje Pharma Co., Ltd.'s P/E ratio?

Kukje Pharma Co., Ltd.'s P/E ratio is 13.5.

Kukje Pharma Co., Ltd.

KRX · 002720
₩3,630+70(+1.97%)Market closedKRX regular session 09:00–15:30 KST
Ask about Kukje Pharma Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Kukje Pharma Co., Ltd. trades at a P/E of 13.5 (undervalued) with modest ROE of 6.1%. 3Y revenue CAGR of 11.5% highlights clear growth momentum.

Ask for details

Company Overview

Kukje Pharma Co., Ltd. is a leading pharmaceutical company based in South Korea, primarily engaged in the research, production, and distribution of medications and medical supplies. The company's primary function is to innovate and provide accessible healthcare solutions by developing a diverse portfolio of prescription and over-the-counter drugs. Kukje Pharma serves various sectors within the pharmaceutical industry, including the development of treatments for chronic illnesses, antibiotics, and specialty medications. It plays a vital role in the healthcare market by addressing critical medical needs and contributing to the improvement of public health standards. As a dynamic entity in the global pharmaceutical industry, Kukje Pharma leverages cutting-edge research and development capabilities to maintain its competitive edge, emphasizing quality and efficacy in its offerings. The company's significant market presence enhances its ability to impact medical markets domestically in South Korea and internationally, aligning with global health trends and regulatory standards.

CEO남영우, 남태훈
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees247

Company Statistics

FY 2025

Profile

₩76,810,190,160Market Cap
₩175,496,223,500Revenue
21.16MShares Out
247Employees

Margins

53.36%Gross
6.14%EBITDA
3.52%Operating
3.67%Pre-Tax
3.25%Net

Valuation

13.48P/E
0.79P/B
0.44EV/Sales
8.95EV/EBITDA
39.06P/FCF

Growth (CAGR)

11.51%Rev 3Yr
6.12%Rev 5Yr
5.46%Op Inc 3Yr
0.47%Op Inc 5Yr
17.21%Net Inc 3Yr
21.05%Net Inc 5Yr

Returns

3.28%ROA
6.09%ROE
4.23%ROIC

Financial Health

₩10,703,213,950Cash & Cash Equivalents
₩73,870,851,370Net Debt
86.56%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Kukje Pharma Co., Ltd. (ticker: 002720) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 247 employees. Market cap is $76.8B.

The current price is ₩3,630 with a P/E ratio of 13.48x and P/B of 0.79x.

ROE is 6.09% and operating margin is 3.52%. Annual revenue is $175.5B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Kukje Pharma Co., Ltd. (002720) Stock Forecast 2026 ₩3,630 — Price, Financials & Analyst Targets | Alpha Lenz